Back to top

Capricor Therapeutics jumps as investors focus on ongoing FDA review and fresh deramiocel update

Capricor Therapeutics (CAPR) is up 78.9% today. Here is some analysis on what might have caused this price movement.

Analysis: The surge appears tied to Capricor’s second-quarter update, which kept deramiocel under active FDA review and argued that a path to approval still exists despite the negative July 29, 2026 advisory committee vote. Investors also seemed encouraged by the publication of the full HOPE-3 Phase 3 dataset in a major medical journal and by signs that the company still has enough cash to keep pushing the program forward.

Details:

  • Capricor said on August 13 that it is still working with the FDA on its biologics license application for deramiocel and planned to provide a regulatory update on its conference call.
  • The company emphasized that the July 29 advisory vote was narrow, non-binding, and focused on cardiomyopathy rather than the HOPE-3 primary endpoint in upper limb function.
  • Capricor highlighted that HOPE-3 results were published in The Lancet, with the primary endpoint met at p=0.029, while noting one revised cardiac endpoint did not remain statistically significant after reverting to the pre-unblinding analysis plan.
  • Cash, cash equivalents, and marketable securities were about $237.9 million at June 30, 2026, which may have reduced immediate financing concerns and supported a risk-on reaction in a heavily event-driven biotech name.

    • Sources:

    Capricor Therapeutics, FDA, The Lancet

    Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

    $CAPR Insider Trading Activity

    CAPR Insider Trades

    $CAPR insiders have traded $CAPR stock on the open market 13 times in the past 6 months. Of those trades, 0 have been purchases and 13 have been sales.

    Here’s a breakdown of recent trading of $CAPR stock by insiders over the last 6 months:

    • KARIMAH ES SABAR has made 0 purchases and 3 sales selling 122,529 shares for an estimated $3,756,395.
    • ANTHONY BERGMANN (CHIEF FINANCIAL OFFICER) has made 0 purchases and 5 sales selling 75,000 shares for an estimated $2,304,850.
    • KAREN KRASNEY (EVP, GENERAL COUNSEL) has made 0 purchases and 5 sales selling 75,000 shares for an estimated $2,304,640.

    To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

    $CAPR Hedge Fund Activity

    We have seen 102 institutional investors add shares of $CAPR stock to their portfolio, and 78 decrease their positions in their most recent quarter.

    Here are some of the largest recent moves:

    To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

    $CAPR Price Targets

    Multiple analysts have issued price targets for $CAPR recently. We have seen 3 analysts offer price targets for $CAPR in the last 6 months, with a median target of $60.0.

    Here are some recent targets:

    • Joseph Pantginis from HC Wainwright & Co. set a target price of $60.0 on 05/13/2026
    • Madison El-Saadi from B. Riley Securities set a target price of $63.0 on 03/13/2026
    • Edward Tenthoff from Piper Sandler set a target price of $58.0 on 03/13/2026

    This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.

    Read full article here »

    In-Depth Zacks Research for the Tickers Above

    Normally $25 each - click below to receive one report FREE:

    Capricor Therapeutics, Inc. (CAPR)